Purespring Therapeutics

Human kidneys
#Kidney disease #MHRA #Nephrology #Phase I trial #Purespring Therapeutics

UK approval for Purespring’s precision nephrology trial

Purespring Therapeutics’ UK Clinical Trial Application (CTA) for a planned Phase I/II study of PS-002 in patients with IgA nephropathy (IgAN) has been approved by the UK Medicines and Healthcare products Regulatory Agency (MHRA), the NHS Health Research Authority (HRA) and Research Ethics Committee (REC).  PS-002 was developed to target… Read More

#News #Regulatory

#European Medicines Agency #Gene therapy #Kidney disease #Orphan drugs #Purespring Therapeutics

EMA orphan designation for IgA nephropathy gene therapy

The European Medicines Agency (EMA) has granted orphan drug designation to Purespring Therapeutics’ PS-002 in IgA nephropathy (IgAN), an autoimmune kidney disease that primarily affects young adults.  Orphan drug designation in the European Union (EU) provides incentives including market exclusivity, protocol assistance (guidance on study design and scientific evaluation) and… Read More

#News #Regulatory

Kidneys
#Financing #Gene therapy #Kidney disease #Purespring Therapeutics

Financing to transform the treatment of kidney diseases

Purespring Therapeutics, a gene therapy company focused on the treatment of kidney diseases, has raised £80 ($105) million in Series B financing. The oversubscribed round was led by Sofinnova Partners, in collaboration with Gilde Healthcare, Forbion, British Patient Capital and founding investor Syncona. Read More

#News